Gritstone, Gilead Partner To Develop Therapeutic HIV Vaccine

Deal Closely Follows COVID-19 Vaccine Effort

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Gritstone will supply the same type of prime-boost vaccine technology it is applying to SARS-CoV-2, and Gilead will supply its own antigens, with the goal of curing HIV.

HIV Vaccine
Gritstone and Gilead are partnering to develop a therapeutic HIV vaccine. • Source: Shutterstock

Less than two weeks after announcing it would seek to develop a vaccine to prevent new resistant strains of SARS-CoV-2, Gritstone Oncology, Inc. is applying the same platform technology as it embarks on another challenging path – developing a therapeutic vaccine with the goal of curing HIV – under a partnership with Gilead Sciences, Inc. potentially worth nearly $800m.

The two companies said 1 February that they would incorporate Gritstone’s prime-boost technology, combining self-amplifying messenger RNA and adenoviral vectors,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

  • ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

     
    • By Jung Won Shin

    The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

More from Scrip